PURPOSE: To examine the effects of lomustine (CCNU), a commonly used nitrosourea, and craniospinal radiation therapy on the subsequent development of restrictive lung disease (RLD) following treatment for malignant brain tumors. PATIENTS AND METHODS: Pulmonary function testing with measurement of lung volume, spirometry, and diffusion capacity was performed in 28 patients who had received CCNU and/or radiation therapy as treatment for a malignant brain tumor. The median age at the time of treatment was 11.4 years (range, 3.9 to 36.7) and radiation therapy was completed 6 months to 11.6 years (median, 2.6 years) before testing. Patients were divided into four groups based on prior therapy. Group 1 received involved-field irradiation and a CCNU-containing chemotherapy regimen (n = 7); group 2, craniospinal irradiation with a boost to the primary tumor site and a CCNU-containing chemotherapy regimen (n = 6); group 3, craniospinal irradiation with a boost to the primary tumor site and a non-CCNU-containing chemotherapy regimen (n = 7); and group 4, craniospinal irradiation with a boost to the primary tumor site without chemotherapy (n = 8). RESULTS: Fourteen patients (50%) had findings consistent with RLD. One of seven patients (14.3%) who received CCNU without spinal irradiation had RLD, whereas 13 of 21 (61.9%) who received spinal irradiation with or without CCNU had RLD (P = .038), including four of eight patients treated with craniospinal irradiation alone. Logistic regression analysis showed that only spinal irradiation was a significant predictor for RLD. Patients who received spinal irradiation were 4.3 times more likely to have RLD than those who did not receive spinal irradiation. CONCLUSION: Spinal irradiation may be a risk factor for the development of RLD.
PURPOSE: To examine the effects of lomustine (CCNU), a commonly used nitrosourea, and craniospinal radiation therapy on the subsequent development of restrictive lung disease (RLD) following treatment for malignant brain tumors. PATIENTS AND METHODS: Pulmonary function testing with measurement of lung volume, spirometry, and diffusion capacity was performed in 28 patients who had received CCNU and/or radiation therapy as treatment for a malignant brain tumor. The median age at the time of treatment was 11.4 years (range, 3.9 to 36.7) and radiation therapy was completed 6 months to 11.6 years (median, 2.6 years) before testing. Patients were divided into four groups based on prior therapy. Group 1 received involved-field irradiation and a CCNU-containing chemotherapy regimen (n = 7); group 2, craniospinal irradiation with a boost to the primary tumor site and a CCNU-containing chemotherapy regimen (n = 6); group 3, craniospinal irradiation with a boost to the primary tumor site and a non-CCNU-containing chemotherapy regimen (n = 7); and group 4, craniospinal irradiation with a boost to the primary tumor site without chemotherapy (n = 8). RESULTS: Fourteen patients (50%) had findings consistent with RLD. One of seven patients (14.3%) who received CCNU without spinal irradiation had RLD, whereas 13 of 21 (61.9%) who received spinal irradiation with or without CCNU had RLD (P = .038), including four of eight patients treated with craniospinal irradiation alone. Logistic regression analysis showed that only spinal irradiation was a significant predictor for RLD. Patients who received spinal irradiation were 4.3 times more likely to have RLD than those who did not receive spinal irradiation. CONCLUSION: Spinal irradiation may be a risk factor for the development of RLD.
Authors: Daniel M Green; Thomas E Merchant; Catherine A Billups; Dennis C Stokes; Alberto Broniscer; Ute Bartels; Murali Chintagumpala; Timothy E Hassall; Sridharan Gururangan; Geoffrey B McCowage; John A Heath; Richard J Cohn; Michael J Fisher; Ashok Srinivasan; Giles W Robinson; Amar Gajjar Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-19 Impact factor: 7.038
Authors: Tseng Tien Huang; Yan Chen; Andrew C Dietz; Yutaka Yasui; Sarah S Donaldson; Dennis C Stokes; Marilyn Stovall; Wendy M Leisenring; Charles A Sklar; Lisa R Diller; Ann C Mertens; Gregory T Armstrong; Daniel M Green; Leslie L Robison; Kirsten K Ness Journal: Pediatr Blood Cancer Date: 2013-10-11 Impact factor: 3.167
Authors: Daniel Gasic; Per Munck Af Rosenschöld; Ivan R Vogelius; Maja V Maraldo; Marianne C Aznar; Karsten Nysom; Thomas Björk-Eriksson; Søren M Bentzen; Nils Patrik Brodin Journal: Radiother Oncol Date: 2018-05-30 Impact factor: 6.280
Authors: Tseng-Tien Huang; Melissa M Hudson; Dennis C Stokes; Matthew J Krasin; Sheri L Spunt; Kirsten K Ness Journal: Chest Date: 2011-03-17 Impact factor: 9.410
Authors: Marzanna Chojnacka; Anna Skowrońska-Gardas; Marzena Morawska-Kaczyńska; Anna Zygmuntowicz-Piętka; Katarzyna Pędziwiatr; Anna Semaniak Journal: Rep Pract Oncol Radiother Date: 2010-02-18
Authors: Miranda M Fidler; Raoul C Reulen; Chloe J Bright; Katherine E Henson; Julie S Kelly; Meriel Jenney; Antony Ng; Jeremy Whelan; David L Winter; Clare Frobisher; Michael M Hawkins Journal: Thorax Date: 2018-05-10 Impact factor: 9.139